Etravirine: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
'''Etravirine''' ('''ETR''',<ref>{{cite web |publisher=[[Department of Health and Human Services]] |work=Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents |url=http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/34/appendix-a--key-to-acronyms |title=Appendix A: Key to Acronyms }}</ref> brand name '''Intelence''', formerly known as TMC125) is a [[drug]] used for the treatment of [[HIV]]. Etravirine is a [[non-nucleoside reverse transcriptase inhibitor]] (NNRTI). Etravirine works by reducing the amount of HIV and increasing the number of CD4 or T cells in the blood. Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine.<ref>{{cite journal |author=Stellbrink HJ |title=Antiviral drugs in the treatment of AIDS: what is in the pipeline? |journal=Eur. J. Med. Res. |volume=12 |issue=9 |pages=483–95 |date=October 2007 |pmid=17933730 }}</ref> Etravirine is marketed by [[Tibotec]], a | '''Etravirine''' ('''ETR''',<ref>{{cite web |publisher=[[Department of Health and Human Services]] |work=Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents |url=http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/34/appendix-a--key-to-acronyms |title=Appendix A: Key to Acronyms }}</ref> brand name '''Intelence''', formerly known as TMC125) is a [[drug]] used for the treatment of [[HIV]]. Etravirine is a [[non-nucleoside reverse transcriptase inhibitor]] (NNRTI). Etravirine works by reducing the amount of HIV and increasing the number of CD4 or T cells in the blood. Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine.<ref>{{cite journal |author=Stellbrink HJ |title=Antiviral drugs in the treatment of AIDS: what is in the pipeline? |journal=Eur. J. Med. Res. |volume=12 |issue=9 |pages=483–95 |date=October 2007 |pmid=17933730 }}</ref> Etravirine is marketed by [[Tibotec]], a subsidiary of [[Johnson & Johnson]]. In January 2008, the [[Food and Drug Administration]] approved its use for patients with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008.<ref>{{cite web |url=http://ap.google.com/article/ALeqM5iCFQR1SKu681KqBBwrXJg1B6q5PAD8U8MS3G0 |title=FDA Approves HIV Drug Etravirine |publisher=[[Associated Press]] |date=January 18, 2008 }}{{dead link|date=November 2012|bot=Legobot}}</ref> It was also approved for use in Canada on April 1, 2008.<ref>{{cite press release |title=First New NNRTI in Nearly a Decade to Benefit Canadians with HIV/AIDS |publisher=Janssen-Ortho Inc. |date=2008-04-01 |url=http://www.janssen-ortho.com/JOI/pdf_files/INTELENCE_Press_Release_E.pdf |accessdate=2008-07-09 |format=PDF }}</ref> | ||
==Category== | ==Category== | ||
Antiretroviral | |||
Antiretroviral | |||
==US Brand Names== | ==US Brand Names== | ||
INTELENCE<sup>®</sup> | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' [[Etravirine description|Description]]''' | ''' [[Etravirine description|Description]]''' | ||
'''| [[Etravirine clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Etravirine clinical pharmacology|Clinical Pharmacology]]''' | ||
| Line 25: | Line 29: | ||
'''| [[Etravirine how supplied|How Supplied]]''' | '''| [[Etravirine how supplied|How Supplied]]''' | ||
'''| [[Etravirine labels and packages|Labels and Packages]]''' | '''| [[Etravirine labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | |||
==References== | ==References== | ||
Revision as of 16:52, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Etravirine (ETR,[1] brand name Intelence, formerly known as TMC125) is a drug used for the treatment of HIV. Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Etravirine works by reducing the amount of HIV and increasing the number of CD4 or T cells in the blood. Unlike the currently available agents in the class, resistance to other NNRTIs does not seem to confer resistance to etravirine.[2] Etravirine is marketed by Tibotec, a subsidiary of Johnson & Johnson. In January 2008, the Food and Drug Administration approved its use for patients with established resistance to other drugs, making it the 30th anti-HIV drug approved in the United States and the first to be approved in 2008.[3] It was also approved for use in Canada on April 1, 2008.[4]
Category
Antiretroviral
US Brand Names
INTELENCE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
References
- ↑ "Appendix A: Key to Acronyms". Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services.
- ↑ Stellbrink HJ (October 2007). "Antiviral drugs in the treatment of AIDS: what is in the pipeline?". Eur. J. Med. Res. 12 (9): 483–95. PMID 17933730.
- ↑ "FDA Approves HIV Drug Etravirine". Associated Press. January 18, 2008.[dead link]
- ↑ "First New NNRTI in Nearly a Decade to Benefit Canadians with HIV/AIDS" (PDF) (Press release). Janssen-Ortho Inc. 2008-04-01. Retrieved 2008-07-09.